Comparable stake leader
ATHOS KG
SEC ownership of BioNTech SE
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001776985.
Disclosed value leader
ATHOS KG
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- BNTX on Nasdaq
- Parsed ownership sources
- 13D/G, 3/4/5, and 13F
- Largest SEC-reported holder
- ATHOS KG
- Latest 13D/G holder
- ATHOS KG
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0001776985
- Issuer location
- Mainz, Germany
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of BioNTech SE (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ATHOS KG
Disclosed value leader
ATHOS KG
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 40%
13D/G row: ATHOS KG
Showing 1-8 of 50 holder rows.
Quick read
ATHOS KG leads the comparable SEC ownership view at 40%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ATHOS KG's linked filing trail.
Comparable ownership
Top 5
ATHOS KG
40%
Medine GmbH
18%
Ugur Sahin
16%
T. Rowe Price Investment Manageme...
2.3%
FMR LLC
2.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ATHOS KG |
13D/G
|
40%
|
$9,712,577,099
101,702,378 shares
|
$0 | 31 Mar 2026 |
| Medine GmbH |
13D/G
Prof. Ugur Sahin, M.D.
|
18%
|
$4,386,515,536
42,178,034 shares
|
$0 | 31 Mar 2025 |
| Ugur Sahin |
13D/G
3/4/5
Chief Executive Officer, 10%+ Owner
|
16%
|
$3,827,288,560
40,076,320 shares
|
$0 | 31 Mar 2026 |
| T. Rowe Price Investment Management, Inc. |
13F
Company
|
2.3%
|
$520,488,000
5,856,073 shares
|
— | 31 Mar 2026 |
| FMR LLC |
13F
Company
|
2.3%
|
$507,437,244
5,709,240 shares
|
— | 31 Mar 2026 |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
Company
|
1.5%
|
$337,185,032
3,793,711 shares
|
— | 31 Mar 2026 |
| Se Flossbach von Storch |
13F
Individual
|
1.5%
|
$327,106,397
3,680,315 shares
|
— | 31 Mar 2026 |
| DODGE & COX |
13F
Company
|
1.4%
|
$326,793,184
3,676,791 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$5,527,960.
Buys
$0
Insiders: 0
Sells
$5,527,960
Insiders: 1
Net
-$5,527,960
Shares: -50,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 50,000
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 50,000 | $0 | $5,527,960 | -$5,527,960 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-13 of 13 reporting-owner rows connected to BioNTech SE. Open a relationship link for the CIK-to-CIK filing trail.
Rows
13
Largest Forms 3/4/5 holder
Sierk Poetting
Net 12M change
-$5,527,960
Latest report
12 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Sierk Poetting | Chief Operating Officer | $44,155,907 | -$5,527,960 | -11% | Filing P/S | 12 May 2026 |
| Ulrich Wandschneider | Director | Mixed | 18 Mar 2026 | |||
| Ozlem Tureci | Chief Medical Officer | Mixed | 18 Mar 2026 | |||
| Helmut Wolfgang Jeggle | Director | Mixed | 18 Mar 2026 | |||
| Michael Motschmann | Director | Mixed | 18 Mar 2026 | |||
| Kylie Jimenez | Chief People Officer | Mixed | 12 May 2026 | |||
| James Timothy Patrick Ryan | Chief Legal Officer and Chief Business Officer | Mixed | 12 May 2026 | |||
| Gomez Ramon Zapata | Chief Financial Officer | Mixed | 12 May 2026 | |||
| Ugur Sahin | Chief Executive Officer, 10%+ Owner | Mixed | 18 Mar 2026 | |||
| Rudolf Staudigl | Director | Mixed | 18 Mar 2026 | |||
| Anja Morawietz | Director | Mixed | 18 Mar 2026 | |||
| Annemarie Hanekamp | Chief Commercial Officer | Mixed | 12 May 2026 | |||
| Nicola Claire Blackwood | Director | Mixed | 18 Mar 2026 |
Recent insider transactions for BioNTech SE
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Gomez Ramon Zapata | BNTX | Performance Share Unit | Award | 15,103 | 15,103 | 12 May 2026 | Direct | |||
| Gomez Ramon Zapata | BNTX | Option (right to buy) | Award | 18,879 | 18,879 | 12 May 2026 | Direct | |||
| James Timothy Patrick Ryan | BNTX | Performance Share Unit | Award | 10,069 | 10,069 | 12 May 2026 | Direct | |||
| James Timothy Patrick Ryan | BNTX | Option (right to buy) | Award | 12,586 | 12,586 | 12 May 2026 | Direct | |||
| Sierk Poetting | BNTX | Performance Share Unit | Award | 10,069 | 10,069 | 12 May 2026 | Direct | |||
| Sierk Poetting | BNTX | Option (right to buy) | Award | 12,586 | 12,586 | 12 May 2026 | Direct | |||
| Kylie Jimenez | BNTX | Performance Share Unit | Award | 8,391 | 8,391 | 12 May 2026 | Direct | |||
| Kylie Jimenez | BNTX | Option (right to buy) | Award | 10,488 | 10,488 | 12 May 2026 | Direct | |||
| Annemarie Hanekamp | BNTX | Performance Share Unit | Award | 10,069 | 10,069 | 12 May 2026 | Direct | |||
| Annemarie Hanekamp | BNTX | Option (right to buy) | Award | 12,586 | 12,586 | 12 May 2026 | Direct | |||
| Sierk Poetting | BNTX | Ordinary Shares | Sale | -11.1% | $5,527,960 | $110.56 | -50,000 | 399,387 | 22 Apr 2026 | See Footnote |
* marks a reported price that did not pass the local price check.